Anti-tumour efficacy of IL-1 and IL-2
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
3260564
Knihovny.cz E-resources
- MeSH
- Sarcoma, Experimental therapy MeSH
- Interleukin-1 pharmacology therapeutic use MeSH
- Interleukin-2 pharmacology therapeutic use MeSH
- Rats MeSH
- Humans MeSH
- Mice MeSH
- Recombinant Proteins therapeutic use MeSH
- Drug Screening Assays, Antitumor MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Interleukin-1 MeSH
- Interleukin-2 MeSH
- Recombinant Proteins MeSH
The potential value of RIL-1 and RIL-2 for local immunotherapy of cancer was compared in the experimental model of MC-induced sarcomas growing in syngeneic (B10) mice. Highly purified recombinant human RIL-1 (Hoffmann-La Roche) and RIL-2 (Amersham) were administered s.c. into the area of lymph nodes draining the growing tumour. Within the dose range examined, RIL-2 was capable of inducing inhibition of tumour growth or complete regression of tumours and the cure of the majority of treated mice. In contrast, RIL-1 could neither inhibit tumour growth nor potentiate the tumour-inhibitory effect of RIL-2.
Interleukin-1 production by immunologically hyporeactive tumour-bearing mice
